PHAT Phantom Pharma to moonshot from upgrade LONG
Updated
PHAT is now targeting 25-34 according to analysts. I am not surprised. It has a pipeline and
is pending approval for a medication product to treat a stomach bacteria that causes chronic
infection and symptoms are often refractory to long and elaborate treatment protocols. The
product is already in Asia and doing well in YoY reports. PHAT has partnered with another
pharma company to make regulatory and marketing inroads in the European market. My
portfolio is already heavy with medtech and pharma but this one is far to promising
with the great upside it presents. I will hit this one hard trying to get the low of day in
pieces and build a position.
is pending approval for a medication product to treat a stomach bacteria that causes chronic
infection and symptoms are often refractory to long and elaborate treatment protocols. The
product is already in Asia and doing well in YoY reports. PHAT has partnered with another
pharma company to make regulatory and marketing inroads in the European market. My
portfolio is already heavy with medtech and pharma but this one is far to promising
with the great upside it presents. I will hit this one hard trying to get the low of day in
pieces and build a position.
Note
NEWS and Analysis seekingalpha.com/article/4480460-phathom-pharmaceuticals-phat-undiscovered-gemNote
Investor Relations investors.phathompharma.com/
Note
Science phathompharma.com/our-science/Note
Back up the truck and tell your friends you would like to borrow their truck for a day or two .....Note
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.